Aging is a risk factor for many age-related diseases, such as type 2 diabetes, atherosclerosis, cardiovascular pathology, cancer, retinopathy, sarcopenia, and others. With the increase in human life expectancy, there is a growing interest in the development of drugs that can delay the onset and progression of aging and age-related diseases. Anti-aging drug testing is carried out on murine models of natural aging, such as C57Bl/6N, Balb/c, or CD-1 strains. A standard study design includes:
- Groups of 25 male and 25 female mice, and the same number of control animals (vehicle dosed).
- Animals maintained in good conventional conditions, 12-hour light/dark cycles, and free access to standardized mouse diet and acidified boiled tap water. If necessary, a calorie-restricted diet is available.
- Treatment begins at the age of 2-3, 5-6, 10-12, 16-18 months (at customer’s request).
- Doses and schemes of treatment are offered by the customer.
- Animals are maintained until natural death. Standard anti-aging effect is monitored by routine tests, such as mortality assessment (daily, except for weekends), body weight (weekly), fasting glucose (monthly), physical activity (quarterly), and gross necropsy (post mortem).
- Specific measurements and tests, such as hematological and clinical chemistry parameters, in combination with behavior tests and more definitive endpoints are available for additional cost.
A typical survival curve of C57BL/6 female mice treated with metformin (M), aspirin (A), and both compounds (AM):
Treatment procedures include invasive (by IV, IP, SC, and PO routes), and noninvasive (with food) methods of drug administration.
Deliverable: A detailed study report including description of study design, experimental data and interpretation.
Sample Submission: Dry compound or compound in pre-made dosing formulation (amount required depends on the dosing levels and schedules). For example, to treat a group of 50 mice at 10 mg/kg, daily (b.i.d.) for 1 month, about 0.45 g of the test compound is required.